

PRIOR AUTHORIZATION CRITERIA

BRAND NAME
(generic)

NAMENDA
(memantine hydrochloride)

Prior Authorization applies only to patients less than 30 years of age.

Status: CVS Caremark Criteria

Type: Initial Prior Authorization with Age Edit

POLICY

FDA-APPROVED INDICATIONS

Namenda and Namenda XR are indicated for the treatment of moderate to severe dementia of the Alzheimer's type.

Compendial Uses

Vascular Dementia^{3, 7, 8}

COVERAGE CRITERIA

The requested drug will be covered with prior authorization for patients less than 30 years of age when the following criteria are met:

- The patient has any of the following diagnoses: A) moderate to severe dementia of the Alzheimer's type, B) vascular dementia

AND

- If the request is for continuation of therapy, the medication continues to provide benefit to the patient [Note: If slowing decline of cognitive function is no longer a goal, or if the patient is rapidly declining, treatment with the medication is no longer appropriate.]

OR

- The diagnosis is supported by a validated cognitive assessment within the past 12 months

REFERENCES

1. Namenda [package insert]. Madison, NJ: Allergan USA, Inc.; November 2018.
2. Namenda XR [package insert]. Irvine, CA: Allergan USA, Inc.; November 2019.
3. Micromedex (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. Available at: <https://www.micromedexsolutions.com>. Accessed May 5, 2021.
4. Lexicomp Online, AHFS DI (Adult and Pediatric) Online, Hudson, Ohio: UpToDate, Inc.; 2021; Accessed May 5, 2021.
5. Rabins P, Blacker D, Rovner B. Practice Guideline for the Treatment of Patients with Alzheimer's Disease and Other Dementias, Second Edition. *Am J Psychiatry*. 2007; 164(12S):1-56.
6. Qaseem A, Snow V, Cross T, et al. Current Pharmacological Treatment of Dementia: A Clinical Practice Guideline from the American College of Physicians and the American Academy of Family Physicians. *An Intern Med* 2008; 148:370-378.
7. Orgogozo JM, Rigaud AS, Stoffler A, et al. Efficacy and safety of memantine in patients with mild to moderate vascular dementia. *Stroke*. 2002; 33:1834-1839.
8. Wilcock G, Mobius H, Stoffier A. A double blind, placebo controlled multicenter study of memantine in mild to moderate vascular dementia. *Int Clin Psychopharmacol*. 2002; 17:297-305.
9. Goldman JS, Hahn SE, Catania JW, et. al. ACMG Practice Guidelines. Genetic counseling and testing for Alzheimer disease: Joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. *Genetics in Medicine* June 2011; 13:597-605.